103 related articles for article (PubMed ID: 26926117)
1. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Nair S; Satapathy SK; Gonzalez HC
Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA;
Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116
[TBL] [Abstract][Full Text] [Related]
3. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Hundemer GL; Sise ME; Wisocky J; Ufere N; Friedman LS; Corey KE; Chung RT
Infect Dis (Lond); 2015; 47(12):924-9. PubMed ID: 26365684
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Gissel C; Götz G; Mahlich J; Repp H
BMC Infect Dis; 2015 Jul; 15():297. PubMed ID: 26223310
[TBL] [Abstract][Full Text] [Related]
5. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Elmasry S; Wadhwa S; Bang BR; Cook L; Chopra S; Kanel G; Kim B; Harper T; Feng Z; Jerome KR; Kahn JA; Saito T
Gastroenterology; 2017 Feb; 152(3):550-553.e8. PubMed ID: 27838287
[TBL] [Abstract][Full Text] [Related]
6. Recurrent hepatitis C after liver transplant.
deLemos AS; Schmeltzer PA; Russo MW
World J Gastroenterol; 2014 Aug; 20(31):10668-81. PubMed ID: 25152571
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation.
Khemichian S; Lee B; Kahn J; Noureddin M; Kim B; Harper T; Esmailian Y; Fong TL
Transplant Direct; 2015 Jul; 1(6):e21. PubMed ID: 27500223
[TBL] [Abstract][Full Text] [Related]
8. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
Grassi A; Ballardini G
World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
[TBL] [Abstract][Full Text] [Related]
9. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M
World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and Simeprevir Combination Therapy for HCV Genotype 1 Infection: Results of a Single-Center VA Experience.
Sclair SN; Hernandez MD; Vance E; Gilinski D; Youtseff H; Toro M; Antoine M; Jeffers LJ; Peyton A
Gastroenterol Hepatol (N Y); 2016 Aug; 12(8):490-497. PubMed ID: 27917084
[TBL] [Abstract][Full Text] [Related]
11. Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study.
Kadla SA; Dar MA; Shah NA; Khan BA; Shah AI; Pathania R; Parveen S
Indian J Pharmacol; 2020; 52(5):372-377. PubMed ID: 33283768
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C: New challenges in liver transplantation.
Filipec Kanizaj T; Kunac N
World J Gastroenterol; 2015 May; 21(19):5768-77. PubMed ID: 26019441
[TBL] [Abstract][Full Text] [Related]
13. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.
Gastroenterol Hepatol (N Y); 2013 Jun; 9(6 Suppl 3):1-18. PubMed ID: 23930097
[No Abstract] [Full Text] [Related]
14. Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.
Pipili C; Cholongitas E
World J Gastrointest Pharmacol Ther; 2015 Nov; 6(4):105-10. PubMed ID: 26558143
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management.
Kakati B; Seetharam A
J Clin Transl Hepatol; 2014 Sep; 2(3):189-96. PubMed ID: 26355427
[TBL] [Abstract][Full Text] [Related]
16. The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.
Tato Marinho RAR
GE Port J Gastroenterol; 2020 Apr; 27(3):147-148. PubMed ID: 32509919
[No Abstract] [Full Text] [Related]
17. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.
Nguyen NH; Yee BE; Chang C; Jin M; Lutchman G; Lim JK; Nguyen MH
BMJ Open Gastroenterol; 2016; 3(1):e000066. PubMed ID: 26966549
[TBL] [Abstract][Full Text] [Related]
19. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.
Yee BE; Nguyen NH; Jin M; Lutchman G; Lim JK; Nguyen MH
BMJ Open Gastroenterol; 2016; 3(1):e000056. PubMed ID: 26966547
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
